Dose Escalation Study of ALX-009 in Healthy Men and Cystic Fibrosis (CF) and Non-CF Bronchiectasis Patients

Inclusion Criteria: * Healthy male subject or * Patient suffering from cystic fibrosis defined as a positive sweat chloride test or CF-causing mutations, documented in the patient's medical record or patient suffering from non-CF and non COPD bronchiectasis with a diagnosis confirmed by a chest CT scan demonstrating bronchiectasis in 1 or more lobes documented in the patient's medical record * Aged between 18 and 50 years inclusive * Subject's Body Mass Index between 18 and 30 kg/m² * Subject with normal blood pressure, heart rate, ECG recording and laboratory parameters at the screening visit * Subject having given a written informed consent prior to selection * Subject covered by Health Insurance System and/ or in compliance with the recommendations of National Law in force relating to biomedical research Specific Inclusion Criteria for patients: * FEV1 more than or equal to 60% of predicted normal value * Subject in a stable state (no exacerbation for 1 month or prescription of antibiotic by intravenous route) * Females of childbearing potential: commitment to consistently and correctly use an acceptable method of birth control for the duration of the trial and for 4 months after the last study drug administration / Female of non-childbearing potential: either surgically sterilized or at least 1 year postmenopausal Exclusion Criteria: * Presence of cardiovascular, pulmonary, gastro-intestinal, hepatic, renal, metabolic, haematological, neurologic, psychiatric, systemic or infectious disease * Frequent headaches and/or migraines, recurrent nausea and/or vomiting * Symptomatic hypotension * Blood donation (including in the frame of a clinical trial) within 2 months before administration * General anaesthesia within 3 months before administration * Presence or history of drug hypersensitivity, or any allergic disease * Medical history of reactions to cow's milk proteins * Subject who can not be contacted in case of emergency * History or presence of drug or alcohol abuse * Positive Hepatitis B surface (HBs) antigen or anti Hepatitis C virus (HCV) antibody, or positive results for Human Immunodeficiency Virus (HIV) 1 or 2 tests * Subject who, in the judgement of the Investigator, is likely to be non-compliant or uncooperative during the study, or unable to cooperate because of a language problem, poor mental development. Specific exclusion criteria for study Parts III and IV: * Known bronchial hyper-reactivity to drug inhalation * Known contra-indication to inhaled salbutamol * Subject with bronchial hyper-reactivity, defined by a positive response to bronchodilator with FEV1 increase ≥ 200 mL Specific exclusion crtieria for patients: * Active allergic bronchopulmonary aspergillosis currently treated * Medical history of allergic bronchopulmonary aspergillosis in the past 2 years.